- Citius stock price reacted to no safety concerns identified by the DMC, to surge 102.86% (YoY) and +108.82% (YTD).
- Citius has prioritized E7777 threatening to derail the company's progression with Mino-Lok.
- Continual medical development may overthrow the use of CVCs due to the high mortality rate of 12%-25% associated with CLABSI.
- With a cash balance of $115.7 million, Citius will likely incur a loss in the E7777 transaction. It requires an upfront payment of $40 million and milestone payments of up to $110 million.
For further details see:
Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization